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Aim: To develop structured guidance, recommendations and techniques for non-pharmacological 
management of cognitive and behavioural impairments in motor neurone disease (MND), called the 
MiNDToolkit. Methods: A 4-round modified-Delphi method was utilised (online and face-to-face 
meeting), supplemented by recent research, recommendations, expertise from allied health-
professionals (AHP) clinicians, researchers and clients. Results: Round-1 (N=47) identified AHPs 
techniques. Round-2 (N=23) and -3 (N=19) used expert consensus, refining general focus, specific 
elements and techniques. Round-4 (N=8) applied personal, lived and occupational experience, 
finalising the general structure and content of specific techniques. Conclusion: The MiNDToolkit is 
composed of multiple tools to structure decision-making through flowcharts, decision-trees and 
checklists, provide information about impairments, assessment recommendations and techniques or 
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Cognitive and behavioural impairment is prevalent throughout all stages of amyotrophic lateral 
sclerosis/motor neurone disease (ALS/MND) occurring in up to 80% of patients [1]. Further, 
ALS/MND exists on a spectrum with frontotemporal dementia, known as the ALS- Frontotemporal 
Spectrum Disorder (ALS-FTLD) / ALS with Frontotemporal Dementia (ALSFTD) [2]. FTD and ALS/MND 
have similar and overlapping profiles of behavioural and cognitive impairment [3-5] and 
approximately 20% of ALS patients can develop FTD or FTD can develop ALS [2,5]. These 
impairments are characterised by executive or language dysfunction, social cognitive deficits or a 
lack of sympathy and empathy as well as changes in behaviour or pre-existing behaviour becoming 
more noticeable [6]. Apathy (or inertia) is one of the most common behavioural impairments 
observed in MND [7], however rigidity and impulsivity are also prominent [8,9].  
These impairments in cognitive and behaviour functioning have been shown to impact negatively 
people living with MND and their families. Multiple studies have shown negative effects on 
wellbeing, quality of life and increased burden on caregivers or family member of people with MND 
[10-13]. A recent systematic review showed that behavioural impairments, specifically apathy or 
impulsivity, were associated with increased burden [14]. More recently, a review suggested that 
while cognitive and behavioural impairment can have impact on both quality of life and caregiver 
burden, they might impact informed decision making and advance planning [15]. Apathy has also 
been shown to affect prognosis, with considerable impact on survival when moderate to severe 
apathy is detected in comparison to mild or no apathy [16]. These behavioural impairments have 
also been suggested to affect treatment compliance and adherence, which may account for the 
impact survival and other practical outcomes. Further, presence of cognitive impairment also seems 
to impact on survival, particularly when executive dysfunction or frontotemporal dementia is 




According to the ALS-FTSD Revised Diagnostic Criteria [2], these changes can be grouped as ALS 
cognitive impairment (ALSci), ALS behavioural impairment (ALSbi), ALS with both impairments 
(ALScbi) and ALSFTD; guidance is also given on assessment of such impairments [2]. As such, multiple 
methods of briefly assessing or screening for cognitive or behavioural impairment have been 
developed and applied, which include the Edinburgh Cognitive and behavioural ALS Screen (ECAS) 
[21], ALS Cognitive Behavioral Screen (ALS-CBS) [22], Mini-Addenbrooke’s Cognitive Examination 
(Mini-ACE) [23] and Motor Neuron Disease Behavioural Instrument (MiND-B) [9] many of which 
were found to be well validated and useful for assessment for these impairments in MND [24].  
 
While the impact of cognitive and behaviour impairment for people with MND and their families 
have been well characterised, with great progress in the development and validation of assessments 
to detect cognitive and behavioural impairment, there has been less advancement in the 
development of guidance, interventions, strategies and/or techniques for the management of such 
issues. The aim of this paper is to describe the process of development of the MiNDToolkit, which is 
a set of structured tools for non-pharmacological management of cognitive and behavioural 
impairment for both healthcare professionals and family members or caregivers. It was developed 
through a compilation of current practices and research, expert opinion, current recommendations 
(from non-profit organisations) and patient and public consultation. As such it is important to 
employ a structured process to gather, synthesize and incorporate information, known as the Delphi 
method [25-27]. Utility of this method allows for facilitated collection of information to achieve 
consensus, from a variety of healthcare professionals and experts, which has been used previously 
to foster development of guidelines within MND [28]. Therefore, in applying this structured 








A modified-Delphi method [25-27] was chosen to structure and refine the information collected 
from all participants/respondents, with authors acting as facilitators. This Delphi method was 
composed of four rounds: three rounds of online consultation, and one round of face-to-face 
consultation. The online consultation was conducted through online surveys using SurveyMonkey 
and Microsoft forms, while continuously taking into account authors’ expertise, current 
recommendations (from organisations such as the English Motor Neurone Disease Association of 
England, Wales and Northern Ireland, Irish Motor Neurone Disease Association) and research in the 
field. Round 1, Round 2 and Round 3 of the survey were used to create a proposed draft of the 
MiNDToolkit. Finally Round 4 was a face-to-face meeting of a Patient & Public Involvement Advisory 
Panel that allowed for comment and review of the proposed draft of the MiNDToolkit. Details of 
each Round are shown in Figure 1 and are described below. 
 






Modified Delphi Method 
Round 1- Existing Practice, Approaches and Techniques Survey  
The questions were designed through iterative discussions by the authors, taking in to consideration 
previous research to understand barriers and practice in relation to cognitive and behavioural 
impairment assessment in MND [29-30]. Furthermore, additional questions were included to 
understand practical management of cognitive and behavioural impairment that healthcare 
professionals might be using. Allied health professionals were invited to an online survey and asked 
to provide information about 1) how cognitive and behavioural impairment is assessed in their 
everyday practice, 2) when and how frequently cognitive and behavioural impairment is assessed 
and 3) approaches/techniques for management of cognitive and behavioural impairment in MND 
that they use (and to rank which they thought were the best). This information was used to guide 
the structure of the MiNDToolkit and produce approaches, techniques and strategies for non-
pharmacological management of cognitive and behavioural impairment in MND, as well as influence 
subsequent rounds of the modified Delphi method. 
 
Round 2- General Clinical & Research Expert Panel Survey  
A list of international clinical and research experts working in the field of MND and FTD worldwide 
(America, Europe, Asia, Australia) was compiled, with the authors selecting experts taking in to 
account research publications within the fields of MND, FTD or MND-FTD, relevance of this to clinical 
management, as well as cognitive and behavioural impairment. The statements for the experts to 
rate for this round were formulated through iterative discussions by the authors, with ALS-FTSD 
diagnostic criteria [2] as a point of reference and to account the practical implications for both 
healthcare professionals and family caregivers or paid caregivers. Experts were invited to online 




healthcare professionals and family members or caregivers. Information was probed in relation to 
non-pharmacological management of cognitive and behavioural impairment in people with MND 
and those with MND-FTD. Statements explored expert’s opinions of the importance relating to 
general practical aspects associated with cognitive and behavioural impairments (daily life, 
communication, knowledge, information, education and information). Statements were rated on a 
4-point Likert scale (Unimportant, Not Very Important, Important, Very Important, ranging from 0 to 
3 respectively). This was used to guide the general structure of the MiNDToolkit. Results of this 
round were fed back to the experts. 
 
Round 3- Specific Clinical & Research Expert Panel Survey 
International clinical and research experts from the list in Round 2 were then asked to provide their 
opinions on more specific practical aspects of cognitive and behavioural impairment. The statements 
for this round were once again formulated through iterative discussions by the authors, taking in to 
account the ALS-FTSD diagnostic criteria [2], the practical implications for both healthcare 
professionals and family caregivers or paid caregivers and the results from Round 2. Specifically, 
experts were asked their opinion on specific statements about implementation of and classification 
using the ALS-FTSD Revised Diagnostic Criteria [2] for health professionals or family/paid caregivers. 
Also, experts were asked about what specific information (Mental Capacity, Advanced Care Planning) 
is important to consider, as well as the importance of previously produced techniques (those from 
Round 1) for healthcare professionals and also caregivers in terms of non-pharmacological 
management of cognitive and behavioural impairment in people with MND and those with MND-
FTD. Statements were rated on a 4-point Likert scale (Unimportant, Not Very Important, Important, 
Very Important, ranging from 0 to 3 respectively). This was used to guide and further refine the 





Round 4- Patient & Public Involvement Advisory Panel 
A half-day, interactive, in-person meeting held at the University of East Anglia, facilitated by authors 
was set to show the MiNDToolkit and to discuss it. The structure of the meeting was to: a) briefly 
introduce cognitive and behavioural impairment in MND and the challenges associated with these; 
b) describe the purpose and the development of the MiNDToolkit; c) review and discussion 
MiNDToolkit itself. In particular, attendees were asked to consider the general format, contents and 
strategies/techniques of the proposed draft of the MiNDToolkit. Attendees were encouraged to 
reflect on their own experiences in relation to cognitive and behavioural impairment in MND. 
Facilitators took notes throughout the meeting, which were synthesised, critically discussed and 
incorporated in the MiNDToolkit after the meeting. 
 
This study received ethical approval from University of East Anglia Faculty of Medicine and Health 
Sciences (FMH) Research Ethics Committee (REC)/ Institutional Review Board (IRB). Participant 
provided informed consent. 
 
Participants 
Round 1, 2 and 3 – online consultation respondents 
Recruitment of allied health professionals occurred through the Motor Neurone Disease Association 
of England, Wales and Northern Ireland, conferences/symposia and various social media outlets. For 
Round 1, 47 professionals completed the whole survey. Another 83 completed the survey partially, 
with a total of 99 individuals interacting with the survey worldwide. All the respondents were 
practicing allied healthcare professionals working with people with MND. 61 international experts 
were selected by authors based on publication within fields of MND, FTD and MND-FTD. 23 experts 




shows the descriptive demographics of respondents who completed the surveys for Rounds 1, 2 and 
3 fully.  
 
Table 1. Demographics and descriptors of respondents from Round 1, 2 and 3 
 Round 1 Respondents 
(N=47) 
Round 2 Respondents 
(N=23) 
Round 3 Respondents 
(N=19) 
Age of respondents, years (Mean, SD) 45.7 (8.5)   
Gender (% F) 87.2   
Education %    
Postgraduate 55.3   
Undergraduate 44.7   
Time working with patient group, years 
(Mean, SD) 
11.0 (8.4) 19.3 (8.6) 11.0 (8.4) 
Part of Multidisciplinary Team % 93.6   
Profession %    
Allied Health Professionals (e.g. 
Occupational Therapists, Speech & 
Language Therapists, Physiotherapists) 
44.7   
Consultant (e.g. Neurologist, Psychiatrist, 
Neuropsychologists, Psychologists, 
Palliative Care) 
29.8 87.0† 68.4‡ 
Specialist Nurses/Nurses 19.1   
Other (e.g. Care Coordinators, Social 
Workers, Researcher) 
6.4 13.0 31.6 
SD = standard deviation. † Neurologist = 47.8%, Psychiatrist = 8.7%, Clinical Neuropsychologist = 21.7%. ‡ Neurologist = 
47.4%, Clinical Neuropsychologist = 21.1%. Not applicable fields in grey. 
 
Round 4- Patient & Public Involvement Advisory Panel members 
Eight attendees (or member) were invited through the Norfolk MND Care and Research Network for 
participation in the advisory panel meeting. The consultation was conducted with 2 current and 1 
former caregiver of people with MND with FTD, 1 person living with MND and their family member 
(both retired healthcare professionals), an MND Specialist Nurse Practitioner (HC), an MND 







Round 1- Existing Practice, Approaches and Techniques Survey  
In terms of assessment, 85.1% of health professional respondents assessed for cognitive or 
behavioural impairment in MND. Of those, 57.5% used a combination of clinical judgement with 
objective measurement, 27.5% used objective measurement only and 12.5% used clinical judgement 
only. Further exploration of objective measurements showed that the ECAS was the most commonly 
used assessment, however the Addenbrooke’s Cognitive Examination-Revised (ACE-R), and its 
different versions, including the Mini-ACE), ALS-CBS and MiND-B were also cited as being used, 
although less commonly. In terms of frequency of assessment, 34.8% of health professional 
respondents said that assessments occur variably (when needed or observed or if something 
changes), and the remainder gave a range of 1 to 4 assessments per year (most commonly 2). Based 
on this, it was decided that the MiNDToolkit should include a flowchart and checklist for healthcare 
professionals to use as a step-by-step guide for their consultations relating to information about and 
assessment of (type and frequency) cognitive and behavioural impairment in MND. Additionally, 
educational materials in relation to the ALS-FTSD Revised Diagnostic Criteria and common cognitive 
and behavioural impairments were also to be included, so as to improve clinical judgement of 
healthcare professionals. Furthermore, recommendations for assessment and timescale were made, 
to emphasise the importance in objective measurement of cognitive and behavioural impairment in 
MND. 
 
Of the respondents surveyed, 46.8% were aware of or used approaches for management of 
cognitive and behaviour impairment in MND. From these 46.8% of respondents, Table 2 shows a 
summary of approaches or techniques ranked as the best by these respondents (healthcare 






Table 2. Best approaches and techniques (N=35) for management of cognitive and 
behavioural impairment in MND from Round 1 
No. of approaches (%) Thematic category Summative details of approaches/techniques 
17 (48%) Structured Support 
Approaches 
- Strategies for managing the deficits or issues identified 
- Strategies for managing the deficits or issues identified 
- Adapting the environment (e.g. more/increasing structure, less 
distraction, safety measures) 
- Break down tasks into manageable small steps 
- Verbal interaction 
- Distraction 
- Routine 
- Physical focus 
- Behavioural approach 
- Person Centred 
- Family work/systemic approach 
- Acceptance and Commitment Therapy 
7 (20%) Personal Support 
Approaches 
- Compassionate communication 
- Increased time 
- Make suggestions and let person come to own conclusions 
7 (20%) Information and 
Education 
- Information about cognitive change, Support 
- Information/Education for carers/families and staff about impairment 
and impact 
- Inform carers on changes and need for their involvement in patient 
care  
2 (6%) Referral to support 
services 
- Referral Occupational Therapist/Clinical Psychologist 
- Refer on to psychological support services 
2 (6%) Medication - Medicate to reduce problem 
 
 
Table 2 shows that Structured Support Approaches were most often endorsed. Best approaches 
noted by allied health professionals was working with families or applying systemic approaches and 
providing caregivers or families with relevant strategies. Additionally, for patients adapting the 
environment (e.g. increasing structure, less distraction, safety measures) as well as breaking down 
tasks in to manageable small steps, verbal interaction and routine were noted as best approaches. In 
terms of Information and Education Approaches and Personalised Support Approaches, these were 




and education for caregivers, family members and staff about the impairments and impacts. 
Additionally, information for caregivers or family members about what impairments to expect and 
the need for their involvement in patient care were noted. Personalised Support Approaches that 
were noted as best by allied health professionals was employing compassionate communication, 
increasing time and giving suggestions so that the person can come to their own conclusions. These 
four groupings of approaches had strong themes of providing support to the family member and 
caregivers, as well as patients. Finally, least endorsed were approaches which involved referral to 
support services (such as Clinical Psychologists or Occupational Therapists) and medication. 
 
Current recommendations, research and authors expertise in the field, in concordance with the 
Round 1 results, produced an initial 7 techniques for healthcare professionals and caregivers or 
family members. These were: 
1. Simplify decision making (e.g. limit choices and reduce open ended questions)  
2. Support problem-solving (e.g. specify the topic being discussed, prompt if needed)  
3. Clarify Complex Information (e.g. break down information, explain terminology that is 
unfamiliar)  
4. Encourage & prompt engagement (e.g. encourage non-verbal responses, use visual and 
verbal cues, engage interest)  
5. Motivate everyone involved (e.g. act as an external motivator to help the person initiate)  
6. Facilitate shared decision making (e.g. encourage decisions to be made with involvement of 
the family/caregiver)  
7. Support the family/caregiver (e.g. support for the family/caregiver in understanding 





Round 2- General Clinical & Research Expert Panel Survey  
According to experts, all statements were comparatively scored as ‘Very Important’ for healthcare 
professionals in terms of specific techniques, adaptations of daily practice and communication style 
when cognitive and behaviour impairment as well as FTD might be present. Further, according to 
experts, all statements were comparatively scored as ‘Very Important’ for family caregivers and paid 
caregivers in terms of information about and examples of cognitive impairment, behaviour 
impairment and FTD, as well as helpful contacts in relation to these problems. Similar to healthcare 
professionals, experts responded that specific techniques and communication styles were ‘Very 
Important’ when cognitive and behavioural impairment, as well as FTD, might be present. See 
Supplementary Table 1 for details of Round 2. 
 
Round 3- Specific Clinical & Research Expert Panel Survey 
According to experts, techniques relating to all individual levels of the ALS-FTSD Revised Diagnostic 
Criteria (ALSci, ALSbi, ALScbi and ALSFTD) were equally important (i.e. ‘Very Important’) for the 
health professionals, whereas techniques for the ALSci, ALSbi and ALScbi levels were rated as 
‘Important’, with the exception of techniques for ALS-FTD which was rated as ‘Very Important‘ for 
family caregivers or paid caregivers. According to experts, the 7 techniques were rated as having 
varying importance for both the family health professionals and family members or paid caregivers. 
All techniques were rated as at least ‘Important’ with none being rated as ‘Unimportant’. See 
Supplementary Table 2 for details of Round 2 results including those for specific techniques.  
 
Additionally, according to experts, for the all ALS-FTSD diagnosis (ALSci, ALSbi, ALScbi, ALS-FTD), 
mental capacity was rated as ‘Very Important’ to consider by healthcare professionals. For ALSci and 




ALS-FTD, earlier advance care planning was rated as ‘Very Important’ to consider by healthcare 
professionals. See Supplementary Table 3 for details of Round 2 Mental Capacity and earlier 
Advanced Care Planning results. 
 
Patient & Public Involvement Advisory Panel  
Overall the panel agreed that the general format of the proposed draft of the MiNDToolkit was well-
structured, pertinent and might be appropriate for use by healthcare professionals and family 
members. The panel advised that further information and educational material on common 
cognitive and behavioural impairments (and how they might be observed) would be beneficial for 
inclusion in the toolkit for both the healthcare professional and the family members or caregivers. 
Additionally, it was noted that further clarification and information on the ALS-FTSD Revised 
Diagnostic criteria terms (ALSci, ALSbi, ALScbi and ALS-FTD) would be useful for reference to 
healthcare professionals. 
 
Specifically, the flowchart and checklist received positive feedback, were understood well and were 
perceived as helpful by all panel members. The panel noted that the toolkit should include multiple 
recommendations for cognitive and/or behavioural assessment, therefore providing options rather 
than favouring one specific assessment tool. In terms of the management techniques, these were all 
noted as valuable for both the healthcare professionals and family members. However, the panel 
members emphasised that fewer techniques with more examples would be more appropriate. Panel 
members with experience with people living with MND-FTD provided additional techniques not 
originally specified by healthcare professionals and experts earlier Rounds. Further, the panel 
members requested that space was provided for healthcare professionals to specify their own 





The panel members extensively discussed mental capacity in relation to cognitive and behavioural 
impairment in MND. While there is a lack of research in this area, panel members emphasised the 
importance of mental capacity and advanced care planning, further supported by panel members 
who are or were carers of people with MND-FTD. It was deduced that healthcare professionals 
should be mindful of facilitating involvement of family members in advanced care planning while 




The resulting MiNDToolkit was composed of 8 tools. Tool 1 is the Flowchart that ensures that steps 
are followed and documented in terms of detection and assessment of cognitive and behavioural 
impairment. Tool 2 is the Checklist to further document ALS-FTSD categorisation, as well as specific 
cognitive and behavioural impairments, guide and document the use of the subsequent tools. Tool 
3a is the Criteria for Categorisation which is for the healthcare professional only and summarises the 
ALS-FTSD diagnostic criteria and categorisation of ALSci, ALSci, ALScbi and ALS-FTD. Tool 3b is the 
Impairments Mapped Against Domains which outlines common cognitive and behavioural 
impairments and their characteristics (executive dysfunction, language problems, issues with social 
cognition/lack of sympathy or empathy, apathy/lack of motivation, disinhibition/impulsivity, 
rigidity/inflexibility). This tool is for both the healthcare professional and the family members. Tool 4 
is Behavioural and Cognitive Assessment which recommends and signposts tools for assessment. 
Tool 5 is for Managing Cognitive Impairments and Tool 6 is for Managing Behavioural impairment. 
These tools provide strategies and techniques that can help both the healthcare professional and 
family member with common cognitive or behavioural impairments. Tool 7 is Mental Capacity and 




areas in relation to cognitive and behavioural impairment. Tool 8 is Clinical Reflective Notes for 
Health Professionals and Follow up: evaluation of strategies used by family and carers which allows 
the healthcare professional to document the effectiveness of strategies and techniques for each of 
the cognitive impairments upon follow-up. Additionally, the MiNDToolkit includes a completion 
inventory to ensure that relevant steps and Tools have been utilised. Please contact the 
corresponding author for further information about the MiNDToolkit. 
 
Discussion 
Here we present the development of the MiNDToolkit for non-pharmacological management of 
cognitive and behavioural change or impairment in MND and MND-FTD. This was produced using 
modified-Delphi method, over several Rounds, and utilising various sources, spanning across current 
research, non-profit recommendations, service user, expert and health professional experience 
which has also supported the creation of a set of techniques and strategies. To further facilitate this, 
a structured delivery method, inclusive of assessment recommendations and forms for 
documentation of decision making has been included so as to supplement the implementation of 
the toolkit and the techniques or strategies within it. The MiNDToolkit is aimed at a range of 
healthcare professionals (e.g. occupational therapists, nurses, speech and language therapists etc.) 
and family members or caregivers so as to help mediate the impact commonly observed cognitive 
and behaviour impairment, inclusive of FTD, while following to the most up to date diagnostic 
criteria [2].  
 
The importance of cognitive functioning and behaviour have been recognised through the National 
Institute for Health and Care Excellence Pathway and Guidance management of MND [31]. Cognitive 




within areas relating recognition and referral, information and support at diagnosis, organisation of 
care, managing other motor/non-motor symptoms and planning for end of life. NICE [31] guidelines 
further focus on a patient’s needs and a tailored approach towards management of cognitive and 
behavioural impairment, with further signposting towards dementia specific guidance [32]. In 
dementia, such problems are addressed by referring to established codes of practice for the 
management of cognitive or behavioural impairment in specialist clinics and community teams [32]. 
However, these dementia guidelines may be difficult to apply to MND, due to this condition’s fast 
progression, the physical disability and communication difficulties [6]. The MiNDToolkit utilises 
adapted techniques that can be used to account for the physical, psychological and communicative 
complexities of MND. 
 
The approaches, techniques and strategies determined from Round 1, showcased that there is a 
multiplicity of methods being employed by healthcare professionals to manage cognitive and 
behavioural impairment, many of which are non-pharmacological. The most commonly used 
approaches, those termed ‘Structured Support Approaches’, thematically clustered around elements 
of already utilised therapeutic, evidence-based techniques, such as Cognitive Stimulation Therapy 
and Behavioural Management Techniques, as well as explicit mention of Acceptance and 
Commitment Therapy. These therapies have been found to be effective in dementia e.g. [33-35]. 
Other approaches were more personalised in terms of providing more general support, education 
and information for family members or caregivers about cognitive and behavioural impairment, 
which are also often observed in management of dementia e.g. [36]. However, the application of 
these approaches occur at variable points in the MND care pathway, due to lack of standardised 
practice or guidance in relation to interventions. There are various barriers that could effect 
implementation of routinely assessing cognitive functioning and behaviour in MND [29,30]. These 




healthcare professionals, patients and family members, but also a lack of advice in terms of 
intervention and management for cognitive and behavioural impairment. Additionally, while the 
survey in Round 1 showed do healthcare professionals utilise their own or adaptive approaches for 
managing cognitive and behavioural impairment, the majority (just over 50%) of healthcare 
professionals did not have any approaches. As such this provides justification for the gap and 
therefore need for structured management approaches for these impairments for a range of 
healthcare professionals. Therefore, development and future use of the MiNDToolkit will aim to 
reduce the advice for management and intervention barrier, through providing a structured method 
to provide this. 
 
The benefits of using a modified-Delphi methodology allowed for continual synthesis and updating 
of information and structure of the MiNDToolkit. Utilizing online surveys for initial rounds of the 
Delphi process, known as e-Delphi, has several advantages [37]. Firstly, it is a cost and time efficient 
method of gathering opinion and information, which also ensures a more diverse range of 
respondents and experts to be involved in the process (due to the global reach of internet-based 
research). The computerised nature of this process allows for quicker and more automated 
processing to arrive to a consensus opinion. A consensus was reached at an early stage within this 
modified-Delphi process (i.e. by Round 3), which can be attributed to the preparatory Round 1 that 
determined existing practice, approaches and techniques. This enabled for the facilitators (RR and 
EM) to create subsequent rounds based on the information gathered in Round 1, while also pooling 
on existing recommendations and current research, and iteratively synthesizing information 
throughout subsequent rounds. A further addition of a Patient & Public Involvement Advisory Panel 
(Round 4) face-to-face meeting ensured that a diverse pool of service users (both family members, 
people living with MND and healthcare professionals) can critically appraise the structure, 




most of the attendees had extensive experience with people affected by cognitive and behavioural 
impairment and MND-FTD. Significantly the Patient & Public Involvement Advisory Panel meeting for 
the MiNDToolkit yielded meaningful changes, as well as additions, improving ecological validity of its 
content for use in the community. Patient & Public Involvement should continue to be a gold 
standard when designing interventions, and recent research has affirmed the positive impact of this 
e.g. [38]. As such, the current lack of evidence-based therapies for managing cognitive and 
behavioural impairment in MND, warrants the application of novel methodology to advance the 
field, such as the modified Delphi method used to design the MiNDToolkit. As assessment and 
awareness of cognitive and behavioural impairment increases, so will the provision for development 
of management techniques that can be incorporated in to the toolkit. Further consideration should 
be given to cultural perceptions of cognitive and behavioural impairment manifestations. This is an 
emerging area within neurodegenerative disease research, with projects looking to investigate 
dementia in developing countries and includes cultural experiences [39], the findings of which could 
potentially be applied to MND and MND-FTD. For example, sensation seeking (akin to 
disinhibition/impulsivity) may be variable dependent on gender and cultural norms e.g. [40], and as 
such may require adaptation to implementation and practice relating to the MiNDToolkit. However, 
further research is needed to further understand perception of culturally behavioural and cognitive 
norms. 
 
In conclusion, the structured research-, experientially- and practically-driven modified-Delphi 
process has produced the MiNDToolkit for non-pharmacological management of cognitive and 
behavioural change or impairment for MND and MND-FTD. The toolkit’s 8-tool configuration 
provides a step-by-step guide for administration and documentation as well as providing educational 
material and recommendations of techniques and strategies for management of these impairments, 




research will look to determine the feasibility of the MiNDToolkit as an intervention within clinical 
practice, with an aim to determine implantation fidelity, explore potential outcomes prior to piloting 
and larger trial research. As such, this will build an evidence for managing cognitive and behavioural 





As awareness and facilitation for assessment of cognitive and behavioural impairment in MND 
increases, it will create opportunity for development or adaptation of techniques, strategies or 
therapies for management. As the evidence-base accumulates, it will require more structured 
methods of incorporating and delivering these management methods for cognitive and behavioural 
impairment, across different aspects of care, for which the MiNDToolkit is equipped.  
With different cultural experiences potentially influencing cognitive and behavioural impairment, as 
well as dementia, these will be of paramount importance to take in to account for assessment and 
management. The techniques, strategies and approaches for management of these impairment 
might therefore need cultural adaptation to facilitate better delivery as well as effective 
management. As such, the MiNDToolkit will be adapted for implementation to different cultures.    
Future studies will look to expand provision for management of cognitive and behavioural 
impairment in MND using non-pharmacological strategies or techniques. This will improve the focus 
on person- and family-centred care and build more evidence toward the utility and applicability of 







 Cognitive and behavioural impairment can occur frequently in amyotrophic lateral sclerosis 
(ALS)/ motor neurone disease (MND), which exists on a spectrum with frontotemporal 
dementia (FTD) 
 There are multiple methods of detection of these impairments however, there are currently 
no structured methods or techniques for management of these impairments for healthcare 
professionals or family members/caregivers 
 An iterative, 4 round modified Delphi method was used to create the MiNDToolkit for 
management of cognitive and behavioural impairment in MND, supplemented with,  current 
expertise, research and recommendations 
 Rounds 1 to 3 (online surveys) included allied health professionals worldwide and clinical 
and research experts to determine the content and structure of the MiNDToolkit. Round 4 
(Patient & Public Involvement advisory panel meeting) utilised experience of specialist allied 
health professionals, people living with MND and family member of people living with MND 
and/or FTD to review and finalise the MiNDToolkit  
 Round 1 collated allied health professionals’ approaches, as well as frequency of assessment 
and various strategies or techniques for managing these impairments. These were 
thematically focused on adaptation, support, education, personalised and evidence-based 
approaches. 
 Round 2 and 3 collectively reinforced the importance of structured education, information 
and understanding of diagnostic criteria for cognitive and behavioural impairment, for both 
healthcare professionals and family members/caregivers. All of these were all incorporated 




 Round 4 further refined the arrangement of tools, content of recommendations and 
examples provided, techniques and practical aspects of the MiNDToolkit based on lived and 
specialist experience 
 The resulting MiNDToolkit is a structured approach to managing cognitive and behavioural 
impairment in MND for healthcare professionals and family members/caregivers. A 
feasibility study is currently underway in the UK.  
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